Provided by Tiger Trade Technology Pte. Ltd.

Akebia Therapeutics

0.9066
-0.0128-1.39%
Post-market: 0.91800.0114+1.26%19:31 EDT
Volume:6.45M
Turnover:5.98M
Market Cap:251.22M
PE:-8.15
High:0.9550
Open:0.9249
Low:0.9055
Close:0.9194
52wk High:3.32
52wk Low:0.8140
Shares:277.11M
Float Shares:269.24M
Volume Ratio:1.01
T/O Rate:2.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1112
EPS(LYR):-0.0208
ROE:-109.38%
ROA:-1.06%
PB:10.04
PE(LYR):-43.62

Loading ...

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 05

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

GlobeNewswire
·
May 04

Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights

GlobeNewswire
·
May 01

Akebia Therapeutics announces annual shareholder meeting via webcast

Reuters
·
Apr 29

Akebia Therapeutics (AKBA) Gets a Buy from Piper Sandler

TIPRANKS
·
Apr 24

Akebia Therapeutics announces annual shareholder meeting via webcast

Reuters
·
Apr 16

Akebia doses first participants in Phase 1 trial of AKB-9090 for acute kidney injury

Reuters
·
Apr 13

Akebia Therapeutics Inc - Akb-097 to Enter Phase 2 Basket Trial in Rare Kidney Diseases in Second Half of 2026

THOMSON REUTERS
·
Apr 13

Akebia Therapeutics Inc - Top Line Data From Phase 1 Trial Expected in Early 2027

THOMSON REUTERS
·
Apr 13

Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium

GlobeNewswire
·
Apr 07

Akebia (AKBA): Buy Rating Backed by Vafseo Momentum and High-Value Renal Pipeline Upside

TIPRANKS
·
Apr 07

Akebia Therapeutics Price Target Maintained With a $4.00/Share by BTIG

Dow Jones
·
Apr 07

Piper Sandler Sticks to Their Buy Rating for Akebia Therapeutics (AKBA)

TIPRANKS
·
Apr 06

H.C. Wainwright Keeps Their Buy Rating on Akebia Therapeutics (AKBA)

TIPRANKS
·
Apr 06

Akebia Therapeutics director Philip J. Vickers files initial beneficial ownership statement

Reuters
·
Apr 04

Akebia grants inducement stock options for 679,900 shares to 13 new hires

Reuters
·
Apr 03

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 03

Press Release: Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors

Dow Jones
·
Apr 02

Akebia Therapeutics to host virtual R&D Day on kidney disease pipeline

Reuters
·
Mar 20

Akebia Therapeutics Earnings Call: Vafseo Drives Growth

TIPRANKS
·
Mar 09